Articles

Clinical Activity of Daratumumab Monotherapy in Heavily Pretreated RRMM
ASH 2015 – Multiple Myeloma
Using a combined analysis of 2 DARA clinical studies, researchers assessed the overall response rates and clinical activity of a 16-mg/kg infusion for the treatment of relapsed and refractory multiple myeloma in heavily treated patients. Read More ›
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
ASH 2015 – Multiple Myeloma
Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial. Read More ›
Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Relapsed MM: Subgroup Analysis Based on Cytogenetic Risk Status of the ENDEAVOR Study
ASH 2015 – Multiple Myeloma
The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups. Read More ›

Page 125 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy